Chemomab Therapeutics Ltd. American Depositary Share (CMMB) Stock Price
CMMBStock
$2.71−20.53%52W
Market Cap$19.86M
P/E—
PEG Ratio—
Div yield—
Beta0.72
CMMB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)62.91%
Price vs S&P 500 (4W)65.74%
VGM Score73.05
CMMB Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.00 | -$0.00 | +0.00%(-$0.00) | |
| Q1 2026 | $0.00 | -$0.00 | +0.00%(-$0.00) | |
| Q4 2025 | -$0.01 | -$0.00 | +70.00%(+$0.01) | |
| Q3 2025 | -$0.04 | -$0.00 | +90.00%(+$0.04) | |
| Q2 2025 | -$0.04 | -$0.02 | +60.00%(+$0.02) |
CMMB Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CMMBChemomab Therapeutics Ltd. American Depositary Share | — | — | B | $2.71 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Chemomab Therapeutics Ltd. American Depositary Share
Chemomab Therapeutics is a clinical-stage biotech company developing CM-101, a monoclonal antibody targeting CCL24 for fibrosis-related diseases with significant unmet medical needs. The company's lead candidate employs a novel mechanism to address liver, skin, and lung fibrosis, with three Phase 2 trials currently underway for rare fibrotic conditions.